Log in to save to my catalogue

Trial of Deferiprone in Parkinson’s Disease

Trial of Deferiprone in Parkinson’s Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_491089

Trial of Deferiprone in Parkinson’s Disease

About this item

Full title

Trial of Deferiprone in Parkinson’s Disease

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2022-12, Vol.387 (22), p.2045-2055

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks.

Alternative Titles

Full title

Trial of Deferiprone in Parkinson’s Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_uu_491089

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_491089

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2209254